1-4 of 4
Jose D. Gonzalez-San Miguel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

Clinical Trials & Observations
Joaquin Martinez-Lopez, Joan Blade, María-Victoria Mateos, Carlos Grande, Adrián Alegre, José García-Laraña, Anna Sureda, Javier de la Rubia, Eulogio Conde, Rafael Martinez, Felipe de Arriba, Maria C. Viguria, Joan Besalduch, Rafael Cabrera, José D. Gonzalez-San Miguel, José Luis Guzman-Zamudio, Maria Carmen Gomez del Castillo, José Maria Moraleda, Juan C. García-Ruiz, Jesús San Miguel, Juan José Lahuerta, for the GEM (Grupo Español de MM) and PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatía Maligna) Cooperative Study Groups
Journal: Blood
Blood (2011) 118 (3): 529–534.
https://doi.org/10.1182/blood-2011-01-332320
Published: 2011
Journal Articles

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Clinical Trials & Observations
Martin S. Tallman, Haesook T. Kim, Pau Montesinos, Frederick R. Appelbaum, Javier de la Serna, John M. Bennett, Guillermo Deben, Clara D. Bloomfield, Jose Gonzalez, James H. Feusner, Marcos Gonzalez, Robert Gallagher, Jose D. Gonzalez-San Miguel, Richard A. Larson, Gustavo Milone, Elisabeth Paietta, Chelo Rayon, Jacob M. Rowe, Concha Rivas, Charles A. Schiffer, Edo Vellenga, Lois Shepherd, James L. Slack, Peter H. Wiernik, Cheryl L. Willman, Miguel A. Sanz
Journal: Blood
Blood (2010) 116 (25): 5650–5659.
https://doi.org/10.1182/blood-2010-06-288613
Published: 2010
Journal Articles

Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.

Martin S. Tallman, MD, Haesook T. Kim, PhD, Charles A. Schiffer, MD, Frederick R. Appelbaum, MD, James H. Feusner, MD, Angela K. Ogden, MD, Lois Shepherd, MD, Cheryl L. Willman, MD, Clara D. Bloomfield, MD, Jacob M. Rowe, MD, Richard A. Larson, MD, Peter H. Wiernik, MD, Guillermo Martin, MD, Chelo Rayon, MD, Javier de la Serna, MD, Concha Rivas, MD, Jose D. Gonzalez-San Miguel, MD, Guillermo Deben, MD, Miguel A. Sanz, MD
Journal: Blood
Blood (2004) 104 (11): 394.
https://doi.org/10.1182/blood.V104.11.394.394
Published: 2004
Journal Articles

Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.

Jose Cervera, MD, Guillermo Martin, MD, Jesus M. Hernandez, MD, Edo Vellenga, MD, Maria J. Calasanz, MD, Jose A. Martinez-Climent, MD, Elisa Luño, MD, Maria T. Ferro, MD, Consuelo Rayon, MD, Marcos Gonzalez, MD, Mar Tormo, MD, Concha Rivas, MD, Elena Amutio, MD, Javier de la Serna, MD, Jose D. Gonzalez-San Miguel, MD, Juan Bergua, MD, Angel Leon, MD, Joaquin Diaz-Mediavilla, MD, Jose Garcia-Laraña, MD, Jordi Esteve, MD, Miguel A. Sanz, on behalf of the PETHEMA Cooperative Group
Journal: Blood
Blood (2004) 104 (11): 2019.
https://doi.org/10.1182/blood.V104.11.2019.2019
Published: 2004